Sana Biotechnology Inc
$ 3.51
3.24%
05 Aug - close price
- Market Cap 946,191,000 USD
- Current Price $ 3.51
- High / Low $ 3.54 / 3.35
- Stock P/E N/A
- Book Value 0.44
- EPS -0.98
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -1.47 %
- 52 Week High 6.55
- 52 Week Low 2.61
About
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
Analyst Target Price
$8.57
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-03 | 2025-11-06 | 2025-08-11 | 2025-05-08 | 2025-03-17 | 2024-11-08 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-03 |
| Reported EPS | -0.14 | -0.16 | -0.15 | -0.16 | -0.2 | -0.23 | -0.27 | -0.32 | -0.32 | -0.41 | -0.41 | -0.59 |
| Estimated EPS | -0.15 | -0.1444 | -0.19 | -0.21 | -0.2 | -0.2428 | -0.27 | -0.24 | -0.22 | -0.38 | -0.45 | -0.43 |
| Surprise | 0.01 | -0.0156 | 0.04 | 0.05 | 0 | 0.0128 | 0 | -0.08 | -0.1 | -0.03 | 0.04 | -0.16 |
| Surprise Percentage | 6.6667% | -10.8033% | 21.0526% | 23.8095% | 0% | 5.2718% | 0% | -33.3333% | -45.4545% | -7.8947% | 8.8889% | -37.2093% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SANA
2026-07-30 04:40:22
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Sana Biotechnology, Inc. (NASDAQ: SANA) breached their fiduciary duties to shareholders. The firm encourages long-term Sana shareholders to contact them to discuss legal options, including seeking corporate governance reforms or the return of funds to the company. They operate on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees.
2026-07-28 03:40:42
This article provides a detailed cash flow statement for Sana Biotechnology Inc (SANA), including quarterly and annual data for operating, investing, and financing activities. It presents key financial metrics such as net income, capital expenditures, and free cash flow, alongside year-over-year percentage changes. The article also includes a FAQ section defining different types of cash flow and their significance for investors.
2026-07-27 21:11:59
This article provides a detailed financial overview of Sana Biotechnology Inc (SANA), including its stock price, market cap, and key financial indicators. It presents current and historical data for income statements, balance sheets, and cash flow statements, along with recent earnings reports and analyst ratings. The report highlights the company's EPS, net profit, assets, liabilities, and equity, offering insights into its financial health over various quarters and fiscal years.
2026-07-27 15:46:44
This article provides a technical analysis of Sana Biotechnology Inc (SANA), detailing its support, resistance, indicators, and moving averages. It covers various technical indicators like MACD, RSI, KDJ, and ATR, along with moving averages (MA5 to MA200), to offer a "Neutral" signal for the stock based on current trends. The analysis indicates a mixed performance from individual indicators but leans towards buy signals from most moving averages.
2026-07-26 03:39:40
Levi & Korsinsky is notifying investors of Sana Biotechnology, Inc. (NASDAQ:SANA) who suffered losses that a lead plaintiff deadline is approaching on May 20, 2025. The class action securities lawsuit alleges that Sana Biotechnology made false and misleading statements about its financial capacity, the promise of certain product candidates (SC291, SC379, and SG299), and the likelihood of funding reductions or discontinuations. Investors affected between March 17, 2023, and November 4, 2024, are encouraged to seek information regarding potential recovery.
2026-07-25 02:46:44
Sana Biotechnology, Inc. (SANA) is a key player in the biotechnology sector, focusing on cell engineering for unmet medical needs like type 1 diabetes and oncology. Despite current unprofitability and negative financial metrics common in R&D-heavy biotech, analysts are optimistic, assigning 8 buy ratings and a significant potential upside of 167.02% from its current trading price of $3.21 to an average target price of $8.57. Strategic collaborations and an innovative product pipeline, such as UP421 and SC451, underscore its growth potential, making it an intriguing consideration for investors in the high-growth healthcare sector, despite the inherent volatility.
